Topical Pramoxine and Hydrocortisone Foam versus Placebo in Relief of Post Partum Episiotomy Symptoms and Wound Healing

1984 ◽  
Vol 29 (2) ◽  
pp. 104-106 ◽  
Author(s):  
I. A. Greer ◽  
A. D. Cameron
Keyword(s):  
Wound Healing ◽  
Randomised Controlled Trial ◽  
Post Partum ◽  
Controlled Trial ◽  
Hydrocortisone Acetate ◽  
Double Blind ◽  
Analgesic Consumption ◽  
Aqueous Foam ◽  
Randomised Controlled

A double-blind randomised controlled trial, comparing pramoxine hydrochloride 1 per cent and hydrocortisone acetate 1 per cent in a mucoadhesive foam base, with simple aqueous foam (B.P.), in relieving episiotomy discomfort and episiotomy healing in 40 patients was carried out. Simple aqueous foam was more effective with regard to wound healing and episiotomy discomfort as measured by analgesic consumption. Pramoxine and hydrocortisone foam offers no advantage over simple aqueous foam in the treatment of post partum episiotomy discomfort.

scholarly journals Efikasi Misoprostol Rektal Intraoperasi Seksio Cesarea Versus Oksitosin dalam Mengurangi Jumlah Perdarahan untuk Mencegah Perdarahan Post Partum

2019 ◽  
Vol 6 (2) ◽  
pp. 37
Author(s):  
Milhan Milhan ◽  
Ariawan Soejoenoes ◽  
Shinta Prawitasari
Keyword(s):  
Randomised Controlled Trial ◽  
Post Partum ◽  
Controlled Trial ◽  
Double Blind ◽  
Randomised Controlled

Latar Belakang : Perdarahan post partum adalah salah satu etiologi kematian ibu. Setelah operasi caesar, uterotonik dalam bentuk infus oksitosin (20-40 IU) atau misoprostol rektal (200-600 μg) diberikan untuk kontraksi uterus pasca operasi pada pasien pada risiko perdarahan post partum. Penelitian ini dibuat membandingkan kedua agen uterotonik  tersebut.Tujuan : Mengetahui perbandingan penggunaan misoprostol rektal tiga tablet (600 ugr) dan penggunaan oksitosin 20 IU  selama operasi seksio cesarea dalam mengurangi jumlah perdarahan untuk mencegah perdarahan post partum di fasilitas kesehatan tingkat lanjut.Metode : Penelitian ini adalah  double blind randomised controlled trial. Populasi penelitian adalah pasien rawat inap ruang kebidanan dan kandungan RSUD Datu Sanggul, Rantau. Besar sampel ditentukan dengan rumus Kirkwood dan Steme sebesar 98. Secara acak peserta dibagi ke kelompok misoprostol dan oksitosin. Farmasi menyediakan obat penelitian dan plasebo dalam bentuk yang tidak dapat dikenali. Untuk kelompok misoprostol disiapkan tablet misoprostol 600 μg untuk digunakan secara rektal ditambah spuit yang sudah diisi sebelumnya larutan saline normal. Kelompok oksitosin disiapkan tablet plasebo untuk digunakan secara rektal ditambah jarum suntik dengan oksitosin 20 IU dan larutan normal saline.Hasil dan Pembahasan: Didapatkan kelompok 1 (misoprostol) dari 42 sampel, yang mengalami perdarahan kurang dari 1000 ml sebanyak 41 sampel (97,6%) dan yang perdarahan lebih dari atau sama dengan 1000 ml sebanyak 1 sampel (2,38%). Sedangkan kelompok 2 (oksitosin) dari 42 sampel yang mengalami perdarahan kurang dari 1000 ml sebanyak 36 sampel (85,7% ) dan yang perdarahan lebih dari 1000 ml sebanyak 6 sampel  (14,3% )Kesimpulan: Ada perbedaan bermakna antara jumlah perdarahan kelompok misoprostol dengan jumlah perdarahan kelompok oksitosin. Karena mean rank kelompok misoprostol lebih rendah dapat disimpulkan bahwa: “Jumlah perdarahan pada penggunaan misoprostol rektal tiga tablet (600 ugr) lebih sedikit dibanding penggunaan oksitosin 20 IU selama operasi seksio cesarea”. Di antara variabel-variabel perancu, riwayat partus lama dan adanya faktor keterlambatan, berhubungan dengan  jumlah perdarahan. Variabel yang dapat digunakan untuk memprediksi jumlah atau banyaknya perdarahan adalah variabel “ada terlambat/tidak”. Kata Kunci: Jumlah Perdarahan, Oksitosin, Misoprostol, Perdarahan Postpartum

scholarly journals Efficacy of maternal B12 supplementation in vegetarian women for improving infant neurodevelopment: protocol for the MATCOBIND multicentre, double-blind, randomised controlled trial

BMJ Open ◽  
2020 ◽  
Vol 10 (5) ◽  
pp. e034987
Author(s):  
Jitender Nagpal ◽  
Manu Raj Mathur ◽  
Swapnil Rawat ◽  
Deepti Nagrath ◽  
Charlotte Lee ◽  
...  
Keyword(s):  
Randomised Controlled Trial ◽  
Post Partum ◽  
Controlled Trial ◽  
Clinical Care ◽  
First Trimester ◽  
Clinical Trial Registry ◽  
Double Blind ◽  
Study Results ◽  
Randomised Controlled ◽  
To Receive

IntroductionVitamin B12 deficiency is widely prevalent across many low- and middle-income countries, especially where the diet is low in animal sources. While many observational studies show associations between B12 deficiency in pregnancy and infant cognitive function (including memory, language and motor skills), evidence from clinical trials is sparse and inconclusive.Methods and analysisThis double-blind, multicentre, randomised controlled trial will enrol 720 vegetarian pregnant women in their first trimester from antenatal clinics at two hospitals (one in India and one in Nepal). Eligible mothers who give written consent will be randomised to receive either 250 mcg methylcobalamin or 50 mcg (quasi control), from enrolment to 6 months post-partum, given as an oral daily capsule. All mothers and their infants will continue to receive standard clinical care. The primary trial outcome is the offspring’s neurodevelopment status at 9 months of age, assessed using the Development Assessment Scale of Indian Infants. Secondary outcomes include the infant’s biochemical B12 status at age 9 months and maternal biochemical B12 status in the first and third trimesters. Maternal biochemical B12 status will also be assessed in the first trimester. Modification of association by a priori identified factors will also be explored.Ethical considerations and disseminationThe study protocol has been approved by ethical committees at each study site (India and Nepal) and at University College London, UK. The study results will be disseminated to healthcare professionals and academics globally via conferences, presentations and publications. Researchers at each study site will share results with participants during their follow-up visits.Trial registration numberCTRI/2018/07/015048 (Clinical Trial Registry of India); NCT04083560 (ClinicalTrials.gov)

Sign in / Sign up

Export Citation Format

Share Document